Bayer’s Quiet Period Begins as Pharma Growth Offsets Legal Overhang

Bayer shares gain 4.39% on ex-dividend day, leading DAX 40 ahead of Q1 earnings on May 12, with focus on pharma growth, debt reduction, and Supreme Court glyphosate case.

The Bayer share price staged a notable recovery on Thursday, climbing more than four percent even as the stock traded ex-dividend. The modest payout of just 0.11 euros per share barely registered as a drag, with the equity closing at 38.05 euros — a daily gain of 4.39 percent. The move made Bayer one of the strongest performers in the DAX 40, a sharp contrast to the roughly 4.5 percent decline it had suffered over the prior 30 days.

The bounce comes as the company enters a quiet period that began on April 20, ahead of its first-quarter earnings release scheduled for May 12. Investors will be scrutinizing the numbers for evidence that the turnaround story is gaining traction. In the fourth quarter of 2025, Bayer posted a loss per share of 3.68 euros on revenue of 11.44 billion euros. Consensus estimates for the full year 2026 call for earnings per share of 4.25 euros — a dramatic swing that the upcoming report will need to support.

While the legal drama surrounding glyphosate continues to dominate headlines, management has been keen to highlight progress in the pharmaceuticals division. The cancer drug Nubeqa and the kidney treatment Kerendia together posted revenue growth of roughly 68 percent in the last fiscal year, helping to offset the impact of expiring patents on older medicines. The heart medication Beyonttra has also exceeded internal expectations since its launch, while the hormone-free menopause treatment Lynkuet is preparing for its European Union debut following a U.S. rollout.

The Supreme Court hearing on Monday in the case of Durnell v. Monsanto added another layer of uncertainty. At issue is whether federal law pre-empts state-level labeling requirements for glyphosate-based products — a legal question with enormous consequences for the more than 100,000 pending lawsuits. Observers described a divided court, with a ruling expected by the end of the current session in June. The provisions set aside for legal cases, totaling roughly 11.8 billion euros, continue to weigh on the balance sheet.

On a year-to-date basis, Bayer shares remain virtually flat, though they trade more than ten percent above their 200-day moving average. The stock is still well off its mid-February high of 49.17 euros. The average analyst price target stands at 42.00 euros, implying roughly ten percent upside from current levels.

Beyond the quarterly numbers, the market will be looking for signs of improved profitability in the Crop Science division, as well as progress on debt reduction. Net debt stood at nearly 30 billion euros after the minimum dividend payout. Chief Executive Bill Anderson’s restructuring plan now faces the pressure of delivering measurable results in the months ahead.